top of page

The Compass Minute


About Us

Compass Laboratory Services is a specialty diagnostics company formed in 2011 with headquarters in Memphis, TN. Compass offers pain management monitoring services and molecular diagnostics of infectious disease with product offerings for urinary tract infections, wound/surgical site infections, sexually transmitted infections, and respiratory infections.

Assisted Living Facilities

Compass offers 3 panels for UTI tests according to patient demographic (community, recurrent, and complicated). The complicated panel tests for more organisms and may be most appropriate for those in assisted living facilities.


For our assisted living facilities, Compass offers a monthly antibiogram report. These reports provide a summary of the pathogens that were detected along with antibiotic resistance. This helps the provider in prescribing appropriate medication. The Compass antibiograms are specific to each client based on the PCR UTI tests ordered.



As traditional respiratory illness season winds down, we continue to see high testing volumes as well as high positivity rates. The three main illnesses are COVID-19, flu, and RSV. RSV is typically associated with children, but we have observed an increase in infections among the adult population. 

Molecular testing offers specific and fast results (most are within 24 hours), offering a wide array of test panels, individual organisms, and drug resistance. Culture & sensitivity tests may take up to 3-5 days.


Compass Laboratory Services has remained focused on fighting the opioid epidemic plaguing our country. Buprenorphine and methadone are two medications used by providers to help patients with opiate addiction. Our laboratory has always provided testing for these drugs and their metabolites, and we are the process of lowering the cutoff levels for buprenorphine and its metabolite norbuprenorphine. The new lower cutoffs can help providers document their patients' medication compliance when prescribing low dose buprenorphine formulations because patients often have very low levels of this drug and metabolite in bodily fluids. Our laboratory will soon be able to confirm buprenorphine and norbuprenorphine down to 2ng/mL in urine specimens, as well as naloxone down to 20ng/mL for situations where the patient is prescribed a buprenorphine/naloxone combination.


Thank you for taking the time to explore some latest updates. Please contact us with any questions.

Compass Laboratory Services

1910 Nonconnah Blvd

Suite 108

Memphis, TN 38132


LinkedIn: Compass Laboratory Services


bottom of page